A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Triciribine (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TCN-PM
- Sponsors Prescient Therapeutics
- 12 Aug 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2022.
- 12 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 11 Mar 2019 Planned End Date changed from 1 Jan 2019 to 1 Dec 2019.